[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599368":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":30,"responsibleParty":54,"collaborators":58,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Iron Deficient patients with underlying bleeding disorders",null,"Subjects ≥15 years old with a history of an inherited bleeding disorder (including von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause) and ferritin \\\u003C50 ng\u002FmL identified during routine clinic evaluation.",[13],"Drug: IV Iron (standard of care)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","IV Iron (standard of care)","Participants will receive IV iron therapy as part of standard management for iron deficiency",[9],[21],{"name":22,"affiliation":23,"role":24},"Nicoletta Machin, DO","University of Pittburgh","PRINCIPAL_INVESTIGATOR",[26],{"name":22,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","(412) 209-7280","MANCHINN@pitt.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Hemophilia Center of Western Pennsylvania","RECRUITING","Pittsburgh","Pennsylvania","15232","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-79.99589,40.44062,{"lat":43,"lon":42},[46,50],{"name":47,"role":27,"phone":48,"phoneExt":10,"email":49},"Deborah Vehec","(412) 209-7564","dvehec@vitalant.org",{"name":51,"role":27,"phone":52,"phoneExt":10,"email":53},"Anuj Kaul","(412) 209-7563","akaul@vitalant.org",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Nicoletta C Machin","Assistant Professor",[59],{"name":60,"class":61},"Health Resources and Services Administration (HRSA)","FED","100599368","impact-of-iv-iron-on-bleeding-symptoms-in-iron-deficient-patients-with-inherited-bleeding-disorders-100599368",false,"NCT07083583","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study","IRON-BD","Inclusion Criteria:\n\n1. Males and Females \\> 15 years of age\n2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)\n3. Evidence of Iron Deficiency (Ferritin \\\u003C 50 ng\u002FmL)\n4. Receiving IV iron at Hemophilia Center of Western Pennsylvania\n5. Willingness to have blood drawn\n6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.\n\nExclusion Criteria:\n\n1. Previous thrombosis, VTE History.\n2. Platelet count \\\u003C 100,000 \\* 109\u002FL\n3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.","ALL","15 Years",{"count":73,"type":74},40,"ESTIMATED","OBSERVATIONAL","This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \\\u003C50ng\u002FdL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes",[78,79,80,81],"Bleeding Disorders","Iron","Platelet","Bleeding",[83,84,85],"Iron deficiency","bleeding disorder","platelet function","2025-10-01",{"date":88,"type":89},"2025-10-03","ACTUAL",{"date":91,"type":89},"2025-08-08",{"date":93,"type":74},"2027-10-01",{"name":56,"class":6},1]